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In type 1 diabetes, loss of tolerance to b-cell antigens results in
T-cell–dependent autoimmune destruction of b cells. The abro-
gation of autoreactive T-cell responses is a prerequisite to
achieve long-lasting correction of the disease. The liver has
unique immunomodulatory properties and hepatic gene transfer
results in tolerance induction and suppression of autoimmune
diseases, in part by regulatory T-cell (Treg) activation. Hence,
the liver could be manipulated to treat or prevent diabetes onset
through expression of key genes. IGF-I may be an immunomod-
ulatory candidate because it prevents autoimmune diabetes when
expressed in b cells or subcutaneously injected. Here, we dem-
onstrate that transient, plasmid-derived IGF-I expression in
mouse liver suppressed autoimmune diabetes progression. Sup-
pression was associated with decreased islet inflammation and
b-cell apoptosis, increased b-cell replication, and normalized
b-cell mass. Permanent protection depended on exogenous
IGF-I expression in liver nonparenchymal cells and was asso-
ciated with increased percentage of intrapancreatic Tregs.
Importantly, Treg depletion completely abolished IGF-I-medi-
ated protection confirming the therapeutic potential of these
cells in autoimmune diabetes. This study demonstrates that a non-
viral gene therapy combining the immunological properties of the
liver and IGF-I could be beneficial in the treatment of the disease.
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n type 1 diabetes, the immune system attacks and
destroys b cells. At the clinical onset of type 1 di-
abetes, 15–40% of b cells are still able to produce
insulin, thus blocking further autoimmune destruc-
tion even at this stage, holding great promise for arresting
disease progression (1). Yet earlier intervention in individ-
uals with documented autoimmune disease but without
clinically manifest diabetes is of course the ultimate goal
in any future intervention strategy to prevent diabetes.
Following this rationale, a growing number of clinical
intervention studies, with the common goal of block-
ing autoimmune disease and reestablishing long-term
tolerance to b cells based on immunomodulation, have
been initiated in the past decade (2).
The liver has unique immunological properties that af-
fect T-cell activation and immune regulation. Although the
liver is an important site for T-cell activation, this takes
place in the context of immunosuppressive cytokines and
a distinctive local immune environment, so that exposure
to antigens often results in tolerance rather than immunity
(3). Tolerance promotion can be mediated, among other
mechanisms, by the induction of regulatory T cells (Tregs)
capable of inhibiting effector responses in the periph-
ery (4). However, the key hepatic cell type responsible
for initiating this phenomenon remains controversial.
Whereas several reports point to hepatocytes, others in-
dicate nonparenchymal cells (NPCs) as the cells that
promote expansion of specific Treg populations able to
limit autoreactive immunity (5). Engineering hepatic cells
to express molecules able to induce Tregs therefore rep-
resents a potential therapeutic approach for the treatment
of autoimmune disorders (5). A number of gene transfer
studies have described the ectopic expression of auto-
antigens in the liver as a means to promote peripheral
control of autoreactive lymphocytes by increasing either
the number and/or the function of Tregs (6). Also, it has
been shown repeatedly, in both mice and nonhuman pri-
mates, that upon in vivo liver-directed gene transfer of
coagulation factor IX, transgene expression has the ca-
pacity to provide therapeutic circulating levels while in-
ducing immune tolerance to the transgene product (7,8).
Thus, in the context of an autoimmune disease such as
type 1 diabetes, a liver-targeted gene therapy approach to
modify peripheral control of autoreactive lymphocytes
offers a unique possibility to prevent development and
progression of the disease. To achieve this would require
efficient and targeted expression to tolerogenic cells as
well as utilization of an appropriate immunomodulatory
transgene. Among the possible immunomodulatory candi-
date genes for type 1 diabetes is IGF-I. We have previously
reported that expression of IGF-I in b cells of transgenic
mice counteracts the cytotoxicity and insulitis induced by
treatment with multiple low doses of streptozotocin (STZ)
(9,10). Moreover, daily subcutaneous administration of
human recombinant IGF-I to prediabetic NOD mice
reduces the severity of insulitis and the incidence of type 1
diabetes (11–13). All these studies reveal IGF-I as a key
factor able to induce protection from type 1 diabetes.
In this work, we report that after delivery of a plasmid
expressing IGF-I to the liver by hydrodynamic tail vein
(HTV) injection, the incidence of diabetes decreases in an
autoimmune mouse model of the disease. We show that
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the expression of IGF-I in liver NPCs leads to an increase
in intrapancreatic Tregs, resulting in decreased pancreatic
infiltration, reduced b-cell apoptosis, and increased b-cell
replication, suggesting a blockage of the autoimmune at-
tack against the pancreas.
RESEARCH DESIGN AND METHODS
Animals. Heterozygous male transgenic mice expressing human interferon
(IFN)-b under the control of the rat insulin promoter-I were used (9). Diabetes
was induced by intraperitoneal injection of very low doses of STZ (25 mg/kg
body weight) dissolved in citrate buffer (pH 4.5) on 5 consecutive days. All
mice were fed ad libitum with a standard chow diet (2018S Teklad Global;
Harlan) and maintained under conditions of controlled temperature and light
(12-h light/dark cycles). Animal care and experimental procedures were ap-
proved by the Ethics Committee in Animal and Human Experimentation of the
Universitat Autònoma de Barcelona.
Plasmids and hydrodynamic injection. The HTV procedure was performed
as described (14). The CAG, hAAT, and CD68 promoters were cloned
substituting the CMV promoter from the commercial pVAX plasmid (Invi-
trogen). Animals in all STZ control (STZ-Con) groups were injected with the
CMV-containing version of pVAX. The hAAT promoter was kindly provided by
Dr. Katherine High, University of Pennsylvania.
b-Cell mass, replication, and apoptosis. Determination of b-cell mass,
replication, and apoptosis was performed as described (9,15).
Hormone and metabolite assays. Blood glucose levels were measured with a
Glucometer Elite analyzer (Bayer, Leverkusen, Germany). Serum insulin con-
centrations were determined by radioimmunoassay (CIS Biointernational, Gif-
Sur-Yvette, France). For the glucose tolerance test, awake mice that were fasted
overnight (16 h) were administered an intraperitoneal injection of glucose (1 g/kg
body weight). The circulating levels of IGF-I were determined by enzyme-linked
immunosorbent assay in 15 mL serum samples using the OCTEIA Rat/Mouse IGF-I
ELISA (Immunodiagnostic Systems, Boldon, U.K.) following the manufacturer’s
instructions.
Isolation of peripheral blood mononuclear cells. Peripheral blood
obtained from mice was diluted 1:1 with PBS plus 0.1% BSA, layered onto an
appropriate volume of Histopaque 1083 (Sigma Aldrich, St. Louis, MO) and
centrifuged at 800g for 20 min. Peripheral blood mononuclear cells were
isolated from the gradient interface and washed in PBS plus 0.1% BSA before
staining with a specific antibody for flow cytometry analysis.
Isolation of hepatic NPCs. Intrahepatic lymphocytes were isolated from liver
as previously described (16).
Flow cytometry and cell sorting. Cells from liver, spleen, peripheral blood,
and pancreas were isolated as described above. CD11b, CD19, CD4, CD8, Gr-1,
F4/80, CD25, FoxP3 (BioLegend, San Diego, CA), and CD11c (BD PharMingen,
San José, CA) antibodies were used. Flow cytometric analysis was performed
on a FC500 MPL (Beckman Coulter, Brea, CA) and data were analyzed using
FCS 3 Express software (De Novo Software, Los Angeles, CA). CD11b+ cells
were sorted using a FacsAria sorter (Becton Dickinson). RNA was isolated
using Qiagen RNeasy Plus Micro kit following manufacturer’s instructions.
In vivo depletion of Tregs and natural killer cells. For Treg depletion, anti-
CD25 antibody (purified anti-mouse CD25 antibody, clone PC61; Biolegend) or
normal rabbit serumwere used. The antibodywas injected intraperitoneally (30
mg in 40 mL of water) the same day as the first IGF-I injection, and a second
administration was given 3 days later. For natural killer (NK) cells depletion,
the antiasialo GM1 antibody (Anti-Mouse Asialo GM1; Diagnostica Longwood)
was injected intraperitoneally (300 mg in 40 mL of water).
RT-PCR and quantitative PCR. One mg RNA was retrotranscribed using the
SuperScript VILO cDNA Synthesis Kit (Invitrogen) following manufacturer’s
instructions. The following specific primers were used: GFP (F: 59AAGTT-
CATCTGCACCACCG39; R: 59TCCTTGAAGAAGATGGTGCGC39); Igf1 (F:
59CTGGGCAACGTGCTGGTTATT39; R: 59GGGTTTGTGAAAGCATCTACGGAA39);
Il10 (F: 59 ACTGCACCCACTTCCCAGT39; R: 59TGTCCAGCTGGTCCTTTGTT39); Il7
(F: 59 ATTATGGGTGGTGAGAGCCG39; R: 59GTTCCTGTCATTTTGTCCAATTCA39);
Tgfb1 (F: 59GCAACATGTGGAACTCTACCAG39; R: 59 CAGCCACTCAGGCG-
TATCA39); RBS (Rps26) (F: 59 ATTCGCTGCACGAACTGCG 39; R: 59 CAGCA-
GGTCTGAATCGTGGT 39).
Statistics. Statistical analyses were performed using GraphPad Prism 4.0
software (GraphPad Software). All data are shown as mean 6 SEM unless
otherwise indicated. Unpaired t test was used to compare between two
groups. Quantitative PCR data were analyzed using REST 2008 software
(Corbett Research, Sydney, Australia).
RESULTS
Gene transfer to liver NPCs after HTV injection of
plasmid DNA. Hepatic cells can be efficiently transduced
with both viral and nonviral strategies to express and se-
crete proteins. We hypothesized that for liver-mediated
induction of tolerance to autoantigens, it would suffice
with transient expression of the candidate gene. Such
short-term expression can be achieved safely through HTV
injection of plasmid DNA (14). However, because the full
repertoire of cells transduced after HTV injection is un-
known, and it is not clear which cells are required for
tolerance induction, we analyzed GFP expression in sev-
eral liver cell populations after injection of plasmid DNA
with different promoter constructs. We found that in ad-
dition to hepatocytes (17), HTV injection of a plasmid-
encoding GFP under control of the ubiquitously expressed
CAG promoter (pCAG-GFP) efficiently transduced Kupffer
cells (KCs) (Fig. 1A, panels A–C, and Supplementary Fig.
1A). In contrast, after HTV injection of a plasmid ex-
pressing GFP under the control of a hepatocyte-specific
promoter (hAAT) (18), only GFP+ hepatocytes (but not
KCs) were detected (Fig. 1A, panels D–F). However, when
a myeloid-specific promoter (CD68) (19) was used to drive
the expression of GFP, only GFP+ KCs could be readily
detected (Fig. 1A, panels G–I, and Supplementary Fig. 1B).
After HTV injection, hepatic expression of GFP plasmids
was maximal at 24 h but progressively declined thereafter
(Supplementary Fig. 2). As a control, injection of an adeno-
associated virus serotype 8 expressing GFP led to long-term
expression of GFP in hepatocytes, but KCs remained GFP-
negative, consistent with the poor tropism of adeno-
associated virus serotype 8 for KCs (20) (Fig. 1A, panels J–L).
Flow cytometry analysis of liver NPCs showed that;20% of
KCs and intrahepatic B lymphocytes, and 5–10% of dendritic
cells (DCs) and T lymphocytes were GFP+ after HTV
injection of pCAG-GFP (Fig. 1B). RT-PCR analysis of FACS-
sorted KC confirmed GFP expression (Fig. 1C), demon-
strating that liver NPCs can express foreign genes after HTV
injection. Thus, this nonviral gene transfer approach may be
used to transiently express genes of interest in liver pa-
renchymal and/or NPCs. Our finding is in disagreement with
previous data that showed plasmid-derived expression after
HTV injection to be confined to hepatocytes (21).
Plasmid-derived expression of IGF-I in liver prevents
the development of type 1 diabetes. We then tested the
ability of the liver to modulate autoreactive lymphocytes
by combining the antidiabetic effects of IGF-I with the
tolerogenic environment of the liver after HTV injection of
IGF-I-expressing plasmids to a transgenic mouse model of
type 1 diabetes. These mice express human interferon-b in
b cells (TgIFN-b), which results in lymphocytic infiltration
of islets and development of overt diabetes when mice are
treated with very low doses of STZ, which do not induce
diabetes in wild-type mice (9,22). By selecting different
promoters, IGF-I was transiently expressed in hepatocytes,
NPCs, or both. First, TgIFN-b mice were treated with STZ
and 1 week later were administered weekly HTV injections
of 5 mg of either pCAG-IGF-I (STZ-CAG-IGF-I) or a non-
coding plasmid (STZ-Con). Non-STZ-treated TgIFN-b mice
were used as controls. Hepatic transgene-specific IGF-I
expression was confirmed by RT-PCR (Fig. 2A). Eight
weeks post-STZ, 90% of STZ-Con mice were highly hyper-
glycemic, whereas;83% of STZ-CAG-IGF-I animals did not
have development of diabetes (Fig. 2B). All mice showed
similar levels of circulating IGF-I (Con, 671 6 62; STZ-Con,
601 6 183; STZ-CAG-IGF-I, 594 6 164 ng/mL). After 10
IGF-I plasmid administrations, STZ-CAG-IGF-I normogly-
cemic mice reached permanent protection from type 1
diabetes and did not require further treatment (Fig. 2B).
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On the contrary, although a similar percentage of animals
were initially protected from diabetes after receiving only
four pCAG-IGF-I administrations, this protection was not
sustained over time and 5 weeks after withdrawing the
IGF-I treatment the percentage of diabetic animals in-
creased to ;43% (Fig. 2C), indicating that a longer IGF-I
treatment was needed to fully protect from immune-
mediated destruction of b cells.
The early stages of diabetic pathogenesis are charac-
terized by insulitis, an inflammation of the islets of Lang-
erhans caused by lymphocytic infiltration. The insulitis
score was determined 15 days and 4 months after STZ
treatment. Approximately 30% of islets in non-STZ-treated
control mice showed lymphocytic infiltration, mainly
consisting of peri-insulitis (Fig. 3A), as previously reported
(9). Fifteen days after STZ treatment, the percentage of
infiltrated islets increased to 70% in STZ-Con mice, with
more than 25% of islets highly infiltrated. In normoglyce-
mic CAG-IGF-I–treated animals, insulitis was significantly
lower, although not completely cleared, as determined by
immunohistochemical and fluorescence-activated cell
sorter analysis (Fig. 3B, C). This decreased infiltration
suggests that pCAG-IGF-I treatment blocked the autoim-
mune attack against b cells. Four months after STZ
FIG. 1. Gene transfer to liver NPCs after HTV injection of plasmid DNA. A: Analysis of GFP and macrophage marker Mac-2 expression in hepatic
cells. GFP and Mac-2 expression were examined 24 h after HTV injection of CAG-GFP (A–C), hAAT-GFP (D–F), and CD68-GFP (G–I) plasmids and
1 month after injection of an adeno-associated vector serotype 8 expressing GFP (AAV8-CAG-GFP) (J–L). White arrows indicate the localization
of KCs. Scale bars: 18 mm (A–C); 22 mm (D–F); 16 mm (G–I); 24 mm (J–L). B: Flow cytometric analysis of GFP expression in liver NPCs 24 h after
HTV injection of pCAG-GFP. Cell markers used to define populations are indicated in parentheses. Results are mean 6 SEM of GFP+ cells within
each population, n = 4 mice per group. *P < 0.05 vs. AAV8-CAG-GFP. C: Expression of GFP in NPCs. A single GFP-specific band was amplified in
FACS-sorted CD11b
+
cells from pCAG-GFP–treated livers. RBS, ribosomal protein S26. Data in B are representative of four independent
experiments. The immunohistochemistry images are representative examples of three different mice per group. (A high-quality digital repre-
sentation of this figure is available in the online issue.)
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treatment, only few insulin-positive cells could be detected
in STZ-Con pancreas, and the remaining islets were small
and highly infiltrated. In contrast, most of the islets in nor-
moglycemic pCAG-IGF-I–treated mice were noninfiltrated
(Fig. 3C).
Plasmid-derived expression of IGF-I in the liver
normalizes pancreatic b-cell mass, insulinemia, and
glucose tolerance. To study if exogenous IGF-I expres-
sion in the liver protected b cells from STZ-induced apo-
ptosis, we identified apoptotic cells in paraffin sections
with TUNEL staining and non-b cells with an antiglucagon,
antisomatostatin, and antipancreatic polypeptide antibody
cocktail. Two weeks after STZ treatment, a great increase
in TUNEL-positive b cells was detected in islets of mock-
treated mice. In contrast, islets of IGF-I-treated mice
showed a 2.5-fold reduction in the number of apoptotic
cells (Fig. 4A). Double immunostaining for insulin and the
proliferation marker Ki67 was used to identify replicating
b cells and determine whether replication of existing b
cells occurred after IGF-I treatment. Two weeks after STZ
treatment, a two-fold increase in Ki67-positive b cells was
detected in IGF-I animals compared with STZ-treated
controls (Fig. 4B). The higher replication rate and de-
creased apoptosis of b cells contributed to a striking in-
crease (more than four-fold) in the number of b cells per
pancreas area in STZ-IGF-I–treated mice compared with
STZ-treated mice (Fig. 4C). As a result, circulating insulin
levels measured 4 months after diabetes induction in CAG-
IGF-I treated mice were normalized (Fig. 4D) and STZ-
CAG-IGF-I mice showed normal tolerance to glucose (Fig.
4E). Thus, the abrogation of autoimmune b-cell attack was
sufficient to preserve b-cell function in STZ-CAG-IGF-I–
treated mice.
Nonparenchymal cell-derived IGF-I protects islets
from diabetes. Because HTV injection mediates trans-
duction of both hepatocytes and nonhepatocyte cells in
the liver (Fig. 1), we used cell-type specific promoters to
restrict IGF-I expression to target cells to discern the
populations responsible for diabetes protection. A plas-
mid expressing IGF-I under the control of the hepatocyte-
specific hAAT promoter (phAAT-IGF-I) was administered
weekly for 4 weeks. Similar to STZ-Con mice, 100% of STZ-
hAAT-IGF-I–treated mice had development of diabetes
(Fig. 5A), indicating that hepatocyte-derived IGF-I is in-
effective in protecting islets from lymphocytic infiltration.
In contrast, when a plasmid expressing IGF-I under the
control of the KC-specific CD68 promoter (pCD68-IGF-I)
was administered to STZ-treated mice, ;60% of mice were
protected from diabetes, whereas 100% of STZ-Con mice
had development of diabetes (Fig. 5B). In this experi-
mental group, the expression in hepatic NPC of IGF-I de-
rived from the plasmid was confirmed by RT-PCR
(Supplementary Fig. 3). These results show that IGF-I ex-
pression in nonparenchymal liver cells is necessary and
FIG. 2. Plasmid-derived expression of IGF-I in liver prevents the development of type 1 diabetes. A: Expression of IGF-I in the liver after HTV
injection of pCAG-IGF-I. RNA was obtained from livers and analyzed by RT-PCR 24 h after the injection of 5 mg of pCAG-IGF-I. Upper lane:
nonretrotranscribed (RT
2
) samples; middle lane: RT+ samples, detection using IGF-I oligonucleotides; bottom lane: RT+ samples, detection using
Rps26 (housekeeping) oligonucleotides. B: Cumulative diabetes incidence after long-term CAG-IGF-I treatment (n = 20 animals per group).
C: Cumulative diabetes incidence on short-term CAG-IGF-I treatment (n = 15 animals per group). Animals were considered diabetic when two
consecutive measurements of blood glucose were >250 mg/dL. Dotted line indicates end of pIGF-I treatment.
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sufficient to suppress diabetes progression. The slightly
lower degree of protection as compared with the CAG-
IGF-I–treated mice could reflect differences in the ex-
pression levels of plasmid-derived IGF-I. Alternatively, it
may suggest that other hepatic cell types also play a role in
preventing diabetes onset. Several studies have shown that
other NPC types such as liver sinusoidal endothelial cells
(23), DCs (24), stellate cells (25), and lymphocytes (26)
can mediate liver-derived immune tolerance in several
animal models of autoimmune diseases.
We measured by flow cytometry the frequency of sev-
eral types of hepatic NPCs after pIGF-I treatment. The
numbers of CD4+ T lymphocytes and NK cells were in-
creased in livers of IGF-I-treated mice, whereas the
FIG. 3. Decreased pancreatic infiltration following IGF-I treatment. A: Insulitis score was determined in control (Con), STZ-Con, and STZ-CAG-
IGF-I animals 15 days after STZ treatment. No infiltration (0), peri-insulitis (<25%), moderate insulitis (<50%), and severe insulitis (>50%).
Results are mean 6 SEM of four mice per group. *P < 0.05 vs. STZ-Con. B: Percentage of infiltrating macrophages (CD11b+), T CD4+ cells, and
T CD8
+
cells in islets. The presence of these cells in islets was quantified by flow cytometry from pancreas extracts 15 days after STZ treatment.
Results are mean 6 SEM of three animals per group. *P < 0.05 vs. Con. #P < 0.05 vs. STZ-Con. C: Immunohistochemical detection of insulin in
pancreatic sections of Con, STZ-Con, and STZ-CAG-IGF-I–treated mice at 2 weeks and 4 months after STZ treatment. Arrows indicate lymphocytic
infiltrate in islets. Data are representative of at least three independent experiments. (A high-quality digital representation of this figure is
available in the online issue.)
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percentage of hepatic CD8+ T cells was decreased in both
CAG-IGF-I–treated and CD68-IGF-I–treated animals (Sup-
plementary Fig. 4A, B). Importantly, no changes were
detected in the frequency of peripheral macrophages, DCs
or lymphocytes with either treatment (Supplementary Fig.
4C, D). The only exception was a decrease in circulating
NK cells in the CAG-IGF-I group (Supplementary Fig. 4C).
IGF-I treatment also led to a significant increase in liver
CD11b+Gr1+ myeloid-derived suppressor cells (MDSCs), in
both STZ-CAG-IGF-I and STZ-CD68-IGF-I mice 2 weeks
post-STZ (Fig. 5C, D). Nevertheless, the percentage of
CD11b+ cells remained unchanged (Fig. 5E). In addition to
being potent suppressors of various T-cell functions,
MDSCs can also induce Treg development (27). The per-
centage of hepatic DCs was also increased (Fig. 5F). To
rule out the possibility that these differences were attrib-
utable to changes in total cell numbers (e.g., presence of
an inflammatory infiltrate in response to higher numbers of
CpG motifs in the IGF-I plasmid as compared with the
noncoding one), the total amount of CD11b+ and CD11c+
cells was measured in a separate cohort of mice that re-
ceived either CAG-IGF-I or noncoding plasmid and com-
pared with an uninjected control group. Importantly, both
plasmid-treated groups had equivalent CD11b+ and
CD11c+ cell numbers in the liver (data not shown). To
further determine the effects of IGF-I expression on DCs,
the DCs from livers of healthy mice were isolated and
cultured in vitro in the presence of exogenous IGF-I and
the expression of key immunosuppressive cytokines was
analyzed by quantitative PCR. IGF-I-treated DCs showed
an increase in transforming growth factor (TGF)-b and
interleukin (IL)-7 expression, whereas IL-10 remained un-
changed (Fig. 5G). TGF-b is critically involved in periph-
eral conversion of conventional T cells to Tregs (28),
whereas IL-7 is a survival factor for Tregs and is expressed
by diabetes-suppressive immature DCs (29).
Roles of Treg and NK cells in diabetes modulation.
Tregs play a major role in the control of type 1 diabetes
(30). To define if changes in Tregs populations under-
lie the ability of hepatic IGF-I expression to protect
from diabetes, we analyzed the percentage of intrahe-
patic and intrapancreatic Tregs after pCAG-IGF-I treat-
ment. A significant (approximately two-fold) increase of
CD4+CD25+Foxp3+ Tregs in the pancreas of IGF-I-treated
animals was found (Fig. 6A). An increase of approximately
two-fold in intrahepatic Tregs, albeit nonsignificant, also
was observed when compared with STZ-Con mice (Fig.
6B). The contribution of Tregs in the prevention of di-
abetes was further studied by depleting this cell population
with an anti-CD25 antibody as previously described (31).
Treg depletion in the absence of STZ failed to trigger di-
abetes onset (Supplementary Fig. 5). As expected from
previous experiments, IGF-I treatment prevented the de-
velopment of diabetes in ;70% of STZ-treated mice,
whereas the depletion of CD25+ lymphocytes completely
abolished the IGF-I-mediated protective effect (Fig. 6C, left
FIG. 4. Plasmid-derived expression of IGF-I in liver normalizes b-cell mass, insulinemia, and glucose tolerance. TUNEL-positive (apoptotic) (A)
and Ki67-positive (replicative) (B) b cells were counted 2 weeks after STZ injection as indicated in RESEARCH DESIGN AND METHODS. Results are mean6
SEM of four mice per group. *P < 0.05 vs. controls (Con). #P < 0.05 vs. STZ-Con. C: b-cell mass was measured 4 months after STZ administration.
Serum insulin levels (D) and glucose tolerance (E) were measured 7 weeks after the first IGF-I administration. Results are mean 6 SEM of four to
five mice per group. For glucose tolerance test, blood glucose levels were measured after an intraperitoneal glucose injection of 1 g/kg body weight.
*P < 0.05 vs. Con. Data are representative of three independent experiments.
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FIG. 5. KC-derived but not hepatocyte-derived IGF-I protects islets from diabetes and increases hepatic myeloid-derived suppressor cells and
expression of IL-7 and TGF-b. A: Cumulative diabetes incidence after hAAT-IGF-I treatment. Dotted line indicates end of treatment (n = 15
animals per group). B: Cumulative diabetes incidence after CD68-IGF-I expression (n = 15 animals per group). Animals were considered diabetic
when two consecutive measurements of blood glucose were >250 mg/dL. Data are representative of at least two independent experiments.
Representative plots (C) and percentage of CD11b+Gr1+ MDSC cells (D). CD11b+ KCs (E) and CD11c+ DCs (F) as determined by flow cytometry
at weeks 2 and 4 after pIGF-I treatment. Results are mean 6 SEM of five animals per group. *P < 0.05 vs. STZ-Con. G: Expression of IL-10, TGF-b,
and IL-7 from in vitro cultured DCs was measured by quantitative PCR as described in RESEARCH DESIGN AND METHODS. *P < 0.05 vs. mock. Data are
representative of two independent experiments. (A high-quality color representation of this figure is available in the online issue.)
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and middle panels). Flow cytometric analysis of periph-
eral blood lymphocytes showed that the levels of Treg
cells declined most significantly at week 1 and gradually
returned to normal within 3 weeks (Fig. 6D). However,
animals remained diabetic.
Our observation of a decrease in circulating and an in-
crease in intrahepatic NK cells after pIGF-I treatment, as
well as recent work from others (32), suggest a prominent
role of this lymphocyte population in diabetes devel-
opment. Also, it has been described for humans and mice
that Tregs can suppress NK cell functions, including cy-
totoxicity (33,34). To assess the relevance of NK cells in
the development of diabetes, we administered an anti-
asialo GM1 antibody to deplete this lymphocyte population
(32,35). Depletion of NK cells reduced the incidence of
diabetes to 60% in STZ-Con animals, whereas it completely
abolished the incidence of the disease in IGF-I-treated
animals (Fig. 6C, right panel). This and the reduction of NK
population in peripheral blood mononuclear cells in IGF-I-
treated animals indicate that prevention from diabetes after
IGF-I treatment may be mediated, at least in part, by a de-
crease in the number of NK cells. Collectively, these results
highlight the central role of Tregs and NK cells, in our animal
model, in preventing or accelerating the disease, respectively.
DISCUSSION
In the current study, we showed that plasmid-derived IGF-I
expression in the liver of prediabetic TgIFN-b mice







Tregs in pancreas (right) and (B) liver was measured by flow cytometry 1 month after the induction of diabetes.
Values are mean 6 SEM of three animals per group. *P < 0.05 vs. STZ-Con. C: Cumulative diabetes incidence after Treg depletion using an anti-
CD25 monoclonal antibody resulted in the loss of IGF-I protective effects (middle panel, n = 6 mice per group). Depletion of NK cells using an
antiasialo GM1 polyclonal antibody (right panel) resulted in all IGF-I-treated animals becoming diabetes-free (n = 6 mice per group). Data are
representative of two independent experiments. D: Depletion of peripheral Treg cells was evaluated 1 and 3 weeks after treatment with anti-CD25
antibody. *P < 0.05 vs. STZ-Con. (A high-quality color representation of this figure is available in the online issue.)
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protects from type 1 diabetes. Whereas concurrent ex-
pression of IGF-I in hepatocytes and NPCs led to disease
protection, NPC-specific IGF-I expression was sufficient to
prevent the onset of the disease. Our results suggest a key
role of NPCs in promoting expansion of Treg popula-
tions able to limit autoreactive immunity because hepatic
IGF-I expression caused enhanced CD4+CD25+Foxp3+ Treg
number and tolerogenic function. We previously proposed
that IGF-I is an interesting candidate to prevent type 1 di-
abetes (9,10). However, to our knowledge, this is the first
study to report the use of a gene therapy approach using
IGF-I as a protective agent against autoimmune diabetes.
First, we characterized the liver cell populations that
were transduced after hydrodynamic injection of plasmid
DNA. It was unexpectedly observed that in addition to
hepatocytes, other hepatic cells were also transduced.
Previous work by others had established that plasmid DNA
injected under HTV conditions could be found within en-
dothelial cells and KCs (17,21). However, actual expres-
sion in NPCs was not detected. The discrepancy with our
work may be attributable to the lack of use of specific
antibodies against NPCs in the previous studies to un-
equivocally identify transduced NPCs. Thus, it is possible
that transduced NPCs were misidentified as being hep-
atocytes. Through immunohistochemical analysis, PCR
and flow cytometry data to show GFP-positive NPCs after
HTV injection, we provide strong evidence that NPCs are
able to express plasmid-derived DNA after HTV. Because
a significant percentage of nonparenchymal immune liver
cells, such as KCs and DCs, are transduced after HTV in-
jection, our data may have implications for the interpretation
of gene therapy experiments targeting the liver using this
nonviral technique.
We took advantage of the transient expression of
transgenes in specific liver cell types mediated by plasmid
HTV to examine whether exogenous IGF-I expression in
the liver could prevent autoimmune diabetes in a trans-
genic mouse model of the disease. TgIFN-b mice treated
with very low doses of STZ comprised the model used in
the study presented herein. We (9,22) and others (35,36)
have established the TgIFN-b mice as a model of type 1
diabetes devoid of some of the limitations present in the
most widely used NOD mouse model; namely, there is
a major gender bias in the incidence of diabetes: ;80% of
disease incidence in NOD females versus ;0–40% in
males. NOD mice harbor a plethora of genetically fixed
immune defects, such as dysfunctional NK cells and lack
of hemolytic complement, that distinguish these mice from
human patients. Also, the incidence of disease is highest
when NOD mice are maintained in a relatively germ-free
environment but dramatically decreases when in conven-
tional housing facilities. It is now acknowledged that type
1 diabetes is such a complex and heterogeneous disease
that the use, or overuse as already pointed out by some
authors (37), of the NOD model as the single model of the
disease may result in a limited landscape of both basic and
translational research in the field of autoimmune diabetes.
On the contrary, TgIFN-b mice show normal reproduction
and life span, and both male and female have development
of diabetes after treatment with very low doses of STZ.
Thus, the use of these transgenic mice offers advantages
because studies in diabetic male or female mice can be
easily programmed, depending on the experimental needs.
Furthermore, when TgIFN-b mice are backcrossed with
NOD mice, development of diabetes is clearly accelerated
(38). These features indicate that TgIFN-b mice may be an
important tool for dissecting tolerance mechanisms and
assaying new treatments for this disease.
A large body of evidence indicates that Tregs play
a central role in retarding and/or suppressing diabetes
onset (39). Recently, Grinberg-Bleyer et al. (40) have
showed that increasing the number of Treg cells locally
in the pancreas can reverse established disease in NOD
mice. In our work, an increase in intrapancreatic Treg cells
was detected in IGF-I-treated mice compared with those
treated with a noncoding plasmid. The induction of TGF-b
production after the exposure of isolated liver-derived
mononuclear cells to IGF-I in vitro suggests that the in-
crease in the number of Tregs may be the result of aug-
mented conversion of conventional T cells into Tregs (41).
However, we also detected an increase in IL-7 transcrip-
tion in cultured DCs exposed to IGF-I. Giannoukakis et al.
(29) have shown that DCs derived from NOD mice engi-
neered ex vivo to become immunoregulatory increased
their prevalence of Tregs via the action of IL-7. Their work
described IL-7 as a survival factor for Tregs. Thus, the
observed increase in Tregs also may be the result of an
improvement in Treg survival.
Despite the importance of Tregs in diabetes prevention
in the experiments presented herein, the participation of
other key players cannot be ruled out. A role for NK cells
in the development of diabetes was also envisaged in this
study. We observed a decrease in the levels of circulating
NK cells in IGF-I-treated animals along with an increase in
intrahepatic NK cells. This observation bears similarities to
the studies of John and Crispe (42) in which they de-
scribed an inverse correlation between the frequency of
activated CD8+ T cells trapped in the liver and their fre-
quency in the circulating pool. We also detected an in-
crease in CD4+ cells in the liver after treatment with IGF-I
plasmids. Studies reporting accumulation of activated
CD8+ cells (43) and NK cells (44) during tolerance in-
duction suggest an important role for the liver in this
process. Whereas CD8+ cell accumulation seems to lead to
destruction of activated CD8+ cells, in the presence of the
antigen NK cells seem to play an anti-inflammatory role in
the liver. In addition, the recent finding that MDSCs affect
NK activity via TGF-b and that downregulation of splenic
and liver NK cell function is inversely correlated with the
marked increase of MDSCs in liver and spleen (45) might
explain the relevance of NK cells in our studies. It also has
been described that Tregs could suppress NK cell func-
tions, including cytotoxicity, NKG2D expression, and IFN
production in humans and mice (33,34).
Collectively, our data suggest that complex interactions
between different cellular types (Tregs, NK cells, and
MDSCs) may be responsible for the observed diabetes
prevention after IGF-I treatment. Although our study using
HTV injection of plasmid DNA to prevent autoimmune
diabetes represents a proof of concept in mice, recent
progress toward a clinically applicable hydrodynamic gene
delivery procedure (46) may favor the translation of such
in vivo approaches for the treatment of autoimmune dis-
eases in human subjects.
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